Genocea Biosciences, Inc. (NASDAQ:GNCA) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued on Monday.
Several other research analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. ValuEngine lowered shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Cowen and Company reiterated an “outperform” rating and issued a $40.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $18.00 price objective (up previously from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Finally, Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Genocea Biosciences currently has an average rating of “Buy” and an average target price of $16.52.
Shares of Genocea Biosciences (NASDAQ GNCA) traded up 0.38% during mid-day trading on Monday, hitting $5.31. 320,728 shares of the stock traded hands. The stock has a 50-day moving average of $4.75 and a 200-day moving average of $5.55. Genocea Biosciences has a 52 week low of $3.28 and a 52 week high of $7.29. The company’s market cap is $151.99 million.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.08). Analysts anticipate that Genocea Biosciences will post ($1.98) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Genocea Biosciences, Inc. (GNCA) Cut to “Hold” at Stifel Nicolaus” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/25/genocea-biosciences-inc-gnca-cut-to-hold-at-stifel-nicolaus.html.
In other Genocea Biosciences news, CFO Jonathan Poole sold 45,000 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $6.00, for a total value of $270,000.00. Following the transaction, the chief financial officer now owns 84,247 shares in the company, valued at approximately $505,482. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 6.70% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in GNCA. Ameriprise Financial Inc. increased its stake in shares of Genocea Biosciences by 34.1% during the 1st quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 5,068 shares during the last quarter. Keybank National Association OH acquired a new position in shares of Genocea Biosciences during the 1st quarter worth $147,000. JPMorgan Chase & Co. acquired a new position in shares of Genocea Biosciences during the 1st quarter worth $217,000. FMR LLC increased its stake in shares of Genocea Biosciences by 0.4% during the 1st quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock worth $26,033,000 after purchasing an additional 18,574 shares during the last quarter. Finally, Segantii Capital Management Ltd acquired a new position in shares of Genocea Biosciences during the 1st quarter worth $160,000. Institutional investors own 59.25% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.